This was the first close of the Series A round. The company is advancing its HIVEC treatment for BCG-unresponsive non-muscle-invasive bladder cancer and plans additional financing rounds for operations, manufacturing scale-up, and broader cancer applications.
About Combat Medical
Medical device innovator developing a patented hyperthermic chemotherapy drug-delivery platform for bladder and other cancers.
Hertfordshire, United Kingdom
Read Company Profile
Source: https://techfundingnews.com/bladder-cancer-innovator-combat-raises-2-6m-for-phase-3-milestone/
Frequently Asked Questions
What type of funding round did Combat Medical raise?
Combat Medical raised a series-a round.
How much did Combat Medical raise in its series-a?
Combat Medical raised $2,600,000 GBP in its series-a.
When did Combat Medical raise its series-a?
Combat Medical raised its series-a on 2026-03-12.
Who invested in Combat Medical's series-a?
The investors in Combat Medical's series-a are: T&J Meyer Family Foundation, NW Angel Fund.
What type of investment was Combat Medical's series-a?
Combat Medical's series-a was a equity investment.
How will Combat Medical use the funds from its series-a?
Combat Medical plans to use the funds for: accelerate clinical development of the hyperthermic chemotherapy platform, support the HIVEC HEAT phase 3 trial, fund late-stage clinical trials, support regulatory preparations, progress toward FDA registration, expand global access to treatment.